Good evening :)
Place Order
Add to Watchlist

Concord Biotech Ltd

CONCORDBIO

Concord Biotech Ltd

CONCORDBIO
Health CarePharmaceuticals
SmallcapWith a market cap of ₹19,698 cr, stock is ranked 340
High RiskStock is 3.08x as volatile as Nifty
1,862.251.10% (-20.70)
1,862.251.10% (-20.70)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹19,698 cr, stock is ranked 340
High RiskStock is 3.08x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹19,698 cr, stock is ranked 340
High RiskStock is 3.08x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
60.0712.900.46%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
50.796.460.51%

Forecast & Ratings

Detailed Forecast 
67%
Analysts have suggested that investors can buy this stock

from 3 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Concord Biotech Limited, a biopharma company, engages in R&D, manufacturing, and marketing of pharmaceutical products in diverse therapeutic segments.

Investor Presentation

View older 

Nov 11, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Loading...

Financial YearFY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue543.85630.50736.35890.441,054.091,129.45
Raw Materialssubtract134.79150.61187.99195.84241.28632.73
Power & Fuel Costsubtract37.3039.8671.6497.65104.97
Employee Costsubtract62.2464.2595.69110.28123.05
Selling & Administrative Expensessubtract31.7431.2167.9082.9391.08
Operating & Other expensessubtract41.732.9819.4222.5124.37
Depreciation/Amortizationsubtract21.2527.5250.0554.0353.5953.75
Interest & Other Itemssubtract1.170.906.135.183.181.30
Taxes & Other Itemssubtract44.5377.8362.5981.93104.46113.75
EPS16.1622.5016.7222.9529.4531.35
DPS3.570.000.476.838.758.75
Payout ratio0.220.000.030.300.300.28

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2024

Annual report

PDF

Investor Presentation

Sep 6PDF
FY 2025

Annual Report Pending

Investor Presentation

Nov 11PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Concord Biotech Ltd63.9312.900.46%
Sun Pharmaceutical Industries Ltd44.966.420.75%
Cipla Ltd30.434.680.84%
Dr Reddy's Laboratories Ltd19.233.800.62%

Price Comparison

Compare CONCORDBIO with any stock or ETF
Compare CONCORDBIO with any stock or ETF
CONCORDBIO
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding44.08%4.97%4.92%8.10%37.93%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

AugSepDec '23MarJunSep4.59%7.30%7.00%6.48%7.11%8.10%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Concord Biotech Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
HSBC Small Cap Fund - Growth - Direct Plan

Growth
0.7935%0.92%0.10%75/109 (-7)
DSP Healthcare Fund - Growth - Direct Plan

Growth
0.5426%3.41%-0.31%11/33 (-2)
Invesco India Multicap Fund - Growth - Direct Plan

Growth
0.3730%1.93%0.14%17/77 (+28)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJun 21, 2024

Final
Final | Div/Share: ₹8.75

Dividend/Share

8.75

Ex DateEx Date

Jun 21, 2024

News & Opinions
Earnings
Concord Biotech consolidated net profit rises 18.17% in the September 2024 quarter

Net profit of Concord Biotech rose 18.17% to Rs 95.74 crore in the quarter ended September 2024 as against Rs 81.02 crore during the previous quarter ended September 2023. Sales rose 18.23% to Rs 310.18 crore in the quarter ended September 2024 as against Rs 262.35 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales310.18262.35 18 OPM %43.1144.11 - PBDT143.65123.00 17 PBT130.34109.70 19 NP95.7481.02 18 Powered by Capital Market - Live

1 day agoCapital Market - Live
Corporate
Concord Biotech to conduct board meeting

Concord Biotech will hold a meeting of the Board of Directors of the Company on 11 November 2024Powered by Capital Market - Live

6 days agoCapital Market - Live
Earnings
Concord Biotech consolidated net profit rises 9.36% in the June 2024 quarter

Net profit of Concord Biotech rose 9.36% to Rs 59.59 crore in the quarter ended June 2024 as against Rs 54.49 crore during the previous quarter ended June 2023. Sales rose 10.76% to Rs 215.80 crore in the quarter ended June 2024 as against Rs 194.83 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales215.80194.83 11 OPM %37.6637.03 - PBDT92.7084.08 10 PBT79.5271.04 12 NP59.5954.49 9 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Concord Biotech schedules board meeting

Concord Biotech will hold a meeting of the Board of Directors of the Company on 9 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live